Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
Rhythm Pharmaceuticals (Nasdaq: RYTM) filed an 8-K disclosing the June 24 2025 Annual Meeting results and a governance change.
- Officer exculpation amendment: Stockholders approved a charter change (55.5 M FOR / 3.5 M AGAINST) extending Delaware-permitted liability protection to certain officers; became effective upon June 25 2025 filing.
- Director elections: Jennifer Good re-elected with 55.6 M votes; Edward T. Mathers retained his seat with 35.2 M votes.
- Auditor confirmation: Ernst & Young LLP ratified for FY-2025 with 60.6 M (99.7 %) FOR.
- Say-on-pay: Executive compensation passed (40.9 M FOR, 18.1 M AGAINST).
- Quorum: 60.7 M votes present, representing 92.7 % of eligible votes.
No operational or financial metrics were updated; the lone material item is the officer liability shield, which may dilute shareholder recourse.
Rhythm Pharmaceuticals director Jennifer L. Good received new equity compensation grants on June 24, 2025, consisting of:
- 7,037 stock options with an exercise price of $63.66 per share, expiring June 23, 2035
- 4,712 restricted stock units (RSUs), each convertible into one share of common stock
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options and RSUs were granted at $0 cost to the director. This appears to be part of the company's regular annual director compensation program. The filing was submitted by Stephen Vander Stoep as attorney-in-fact for Jennifer Good.
Rhythm Pharmaceuticals (RYTM) director Edward T. Mathers received new equity compensation grants on June 24, 2025. The awards consist of:
- Stock Options: 7,037 options with an exercise price of $63.66, exercisable until June 23, 2035
- Restricted Stock Units (RSUs): 4,712 units, each convertible to one common share
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options provide the right to purchase shares at the specified strike price, while the RSUs represent a contingent right to receive shares upon vesting with no purchase requirement. This compensation structure aligns the director's interests with long-term shareholder value.
Rhythm Pharmaceuticals (RYTM) – Form 4 insider filing
Director Christophe Jean reported two equity awards dated 24 Jun 2025:
- Stock option: 7,037 shares of common stock, exercise price $63.66, expiration 23 Jun 2035. The option vests in full on the earlier of 24 Jun 2026 or the day before the company’s 2026 annual shareholder meeting, subject to continued board service.
- Restricted stock units (RSUs): 4,712 units, each convertible into one common share. Vesting schedule mirrors the option grant; the RSUs have no expiration date.
Both grants are coded "A" (acquired) and were made directly to the reporting person. Following the transactions, Jean beneficially owns 7,037 stock options and 4,712 RSUs; no common shares were reported in Table I and no sales occurred.
The filing represents routine non-cash director compensation and does not disclose any open-market purchase or sale of Rhythm Pharmaceuticals stock.
Form 4 overview: Rhythm Pharmaceuticals (RYTM) disclosed that director Stuart A. Arbuckle received new equity awards on 24 June 2025.
The filing records the grant of 7,037 stock options with a $63.66 exercise price, expiring 23 June 2035, and 4,712 restricted stock units (RSUs). Both awards fully vest on the earlier of 24 June 2026 or the day immediately before the 2026 annual stockholder meeting, provided the director remains on the board. No non-derivative common-stock transactions were reported, and the director now beneficially owns the full amount of these derivative securities.
This appears to be routine annual board compensation that aligns the director’s incentives with shareholders and carries minimal dilution, offering little direct impact on Rhythm’s near-term financial outlook.
Form 4 snapshot: On 06/24/2025, Rhythm Pharmaceuticals (ticker RYTM) filed a Form 4 reporting new equity awards to director Lynn A. Tetrault.
- Stock options: 7,037 options with a $63.66 exercise price, expiring 06/23/2035. Vest in full on the earlier of 06/24/2026 or the day before the 2026 annual meeting, subject to continued board service.
- Restricted stock units (RSUs): 4,712 units; each RSU converts into one common share. Vesting schedule matches the option grant; no expiration date.
- Post-grant holdings: 7,037 derivative securities (options) and 4,712 RSUs are now reported as beneficially owned. No common shares were bought or sold, and no dispositions occurred.
The filing reflects routine director compensation designed to align incentives; it does not disclose any share sales, purchases with cash, or changes to non-derivative ownership.
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) – Form 4 insider filing dated 26 June 2025
Director David W. J. McGirr reported the receipt of two new equity grants on 24 June 2025:
- 7,037 non-qualified stock options with an exercise price of $63.66, expiring 23 June 2035. The options vest in full on the earlier of 24 June 2026 or the day before the company’s 2026 annual shareholder meeting, subject to continued board service.
- 4,712 restricted stock units (RSUs), each convertible into one share of common stock, subject to the same vesting schedule as the options. RSUs have no expiration date.
Both transactions were coded “A” (acquired) and were reported as direct holdings. No shares were sold or otherwise disposed of, and no Rule 10b5-1 trading plan was indicated.
Following the grants, McGirr’s directly held derivative interests consist of 7,037 options and 4,712 RSUs. The filing does not disclose his current ownership of fully vested common shares, and there were no cash proceeds to the insider or the company at grant.
Investment view: The activity reflects routine annual director compensation. While insider equity awards can strengthen alignment between directors and shareholders, the aggregate 11,749 potential shares represent an immaterial fraction of Rhythm’s outstanding share count and pose only minimal future dilution. The absence of open-market purchases means there is no immediate demand signal for the stock.